Mesoblast Limited vs ZIM Integrated Shipping Services Ltd — how do they compare? Mesoblast Limited trades at $14.29 (market cap $1.75B), while ZIM Integrated Shipping Services Ltd trades at $29.99 (market cap $3.65B). The key difference: ZIM Integrated Shipping Services Ltd is far larger — about 2.1× Mesoblast Limited's market cap, and ZIM Integrated Shipping Services Ltd pays a 20.16% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and ZIM Integrated Shipping Services Ltd for 27 Days on average.
| MESO | ZIM | |
|---|---|---|
Market Cap | $1.75B | $3.65B |
Volume | 239,027 | 1,068,475 |
Sector | Health | Industrials |
52-Week High | $20.96 | $30.51 |
52-Week Low | $13.19 | $12.44 |
Typical Hold Time | 15 Days | 27 Days |
Enterprise Value | $1.83B | $7.32B |
Dividend Yield | — | 20.16% |
Signals from Pluang's Aura AI — not financial advice
MESO trades at $14.29, up 2.51% today, amid bearish technical signals but positive fundamental developments. The stock shows strong revenue growth with FY2026 reaching $120 million, though profitability remains negative. Recent FDA approval for Ryoncil's potency assay and completion of Phase 3 back pain trials provide catalysts. Technical indicators show oversold conditions with RSI at 22.4, while moving averages signal bearish momentum.
Investment outlook balances high growth potential against persistent losses. The expanding Ryoncil market share and pipeline progress offer upside, but negative margins and cash burn pose risks. Analyst consensus leans bullish with 45% buy ratings, yet the stock faces execution challenges in achieving profitability amid competitive pressures.
ZIM Integrated Shipping Services trades at $30.26, up 0.9% today and near its 52-week high of $30.96. The stock shows bullish technical momentum with strong moving average signals, though RSI indicators suggest potential overbought conditions. Fundamentally, Q2 2026 earnings beat expectations with $0.53 EPS versus -$0.02 expected, driven by 9% revenue growth to $1.8 billion. The company faces acquisition uncertainty with Hapag-Lloyd's $35 per share offer pending Israeli government approval.
Investment outlook remains mixed with strong operational performance offset by merger uncertainty. The stock trades at attractive valuations (P/S 0.57, P/B 0.94) but faces headwinds from declining 2026 profit margins (2.15% vs 6.94% in 2025). Analyst consensus leans cautious with 67% hold ratings, while technical indicators suggest near-term resistance at current levels. Key risks include government approval of acquisition and volatile shipping rates.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →